Contribute Try STAT+ Today

Rise and shine, everyone, another challenging day is on the way. And while it will be like this for some time, perhaps it may be best to take one day at a time and keep focused on the matters at hand. We are doing so with a little help from, yes, a cup or three of stimulation. And of course, we invite you to join us. Remember, a prescription is not required. And now, here are a few tidbits to move you along. Best of luck today and do stay safe.

A growing number of companies are postponing or curtailing clinical trials due to Covid-19, according to a survey conducted by Continuum Clinical, a consulting firm that works with drug makers and trial sites, and the Association of Clinical Research Professionals. Nearly one-third of study sites fear total closure as stay-at-home orders and patient concerns over interacting with health care professionals continue to increase. And 77% of sites indicated at least one of their current clinical trials had been put on hold or cancelled in recent weeks.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.